MSB 5.24% $1.11 mesoblast limited

jb morgan health conference = outstanding

  1. 632 Posts.
    From one of the premier health conferences in the world... Many of the big boys with deep pockets in attendance... What they heard was more validation on the strength of this company, their outstanding pipeline, impressive risk management, strong cash position and partnerships and most of all the paradigm shifting technologies......
    Short term here is what we have to look forward too!!! 2012 will be huge...

    Value inflexion points – near term
    ?Teva + Mesoblast meeting with FDA re commencement Phase 3 trial for congestive heart failure
    ?completion of Phase 2 spinal fusion trials
    ?completion of Phase 2 disc repair trial
    ?FDA clearance of IND to begin Phase 2 trial in Type 2 Diabetes
    ?expanding the intravenous product franchise, e.g. lung diseases
    ?further partnering opportunities – optimal timing
    26
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.